Gardasil, its HPV vaccine, posted a 17% decline in sales to $1.55 billion, primarily due to lower demand in China.

Under its restructuring program, Pfizer said it remains on track to deliver $4.5 billion in cost savings by the end of 2025.

We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.

Last week was certainly memorable, and it looks like this week is off to a similar start.

The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025.

Trade war between US, Canada, and Mexico could cause severe economic damage, raise prices, and disrupt supply chains in key industries.

What we got today, of course, was advance GPD, which is the earliest measure and also the most likely to provoke a reaction in stocks.

Anxiety about the competitive threat from Chinese artificial intelligence lab DeepSeek triggered a sharp selloff in US equities on Monday, with the worst of the decline centered in tech.

The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech.

The agreement, which spans up to four years, allows 17 participating countries access to Moderna’s vaccine in various formats.

The firm’s medical-loss ratio (MLR) rose to 92.4% due to Medicaid-related costs but was better than expected.

During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually.

In 2023, Moderna initiated a Phase 1/2 study to assess the safety and immunogenicity of its investigational bird flu vaccine, mRNA-1018, in healthy adults aged 18 and older.

Wall Street saw a strong preference for small and mid-cap equities, with the Russell 2000 index leading the market as investors bet on more domestic-friendly policies following Donald Trump's inauguration on Jan. 20 as the 47th U.S. president.